Down's syndrome and acute lymphoblastic leukaemia: clinical features and response to treatment.
about
Clinical and genetic features of pediatric acute lymphoblastic leukemia in Down syndrome in the Nordic countries.Methotrexate-induced side effects are not due to differences in pharmacokinetics in children with Down syndrome and acute lymphoblastic leukemia.Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children's Oncology GroupAttentional ability among survivors of leukaemia treated without cranial irradiation.Possibilities for tailored and targeted therapy in paediatric acute myeloid leukaemia.Down syndrome and acute lymphoblastic leukaemia.Haematology of Down syndromeInsights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndromeMalignancy in children with trisomy 21.A comparison of acute lymphoblastic leukemia in Down syndrome and non-Down syndrome children: the role of trisomy 21.Unique clinical and biological features of leukemia in Down syndrome children.Acute lymphoblastic leukaemia in children with Down syndrome: an updated review.Child and adolescent Down syndrome-associated leukaemia: the Irish experience.Acute lymphoblastic leukemia: a comprehensive review and 2017 updateSupportive care utilization and treatment toxicity in children with Down syndrome and acute lymphoid leukaemia at free-standing paediatric hospitals in the United States.Long-term sequelae in survivors of childhood leukemia with Down syndrome: A childhood cancer survivor study report.Long-term prognosis of children with Down's syndrome and leukaemia: a 34-year nation-wide experience.Equal frequency of TEL/AML1+ acute lymphoblastic leukemia in children with and without Down syndrome.Equal frequency of TEL/AML1 rearrangements in children with acute lymphoblastic leukemia with and without Down syndrome.Acute lymphoblastic leukemia and Down syndrome: the collaborative study of the Tokyo Children's Cancer Study Group and the Kyushu Yamaguchi Children's Cancer Study Group.Outcome in children with Down's syndrome and acute lymphoblastic leukemia: role of IKZF1 deletions and CRLF2 aberrations
P2860
Q33615910-17CE55EA-6423-4E17-97EC-5DBE1538E5E7Q33952766-DF40F2E3-3E3F-4B6D-BFF0-0841CD625334Q34122298-D81BFF5E-8195-4A42-A929-8F13169D3E32Q35275307-C28B9ABE-5D64-4CF7-9435-08BB18DB2E0BQ35921471-E9FC7CE2-428D-4A58-BBC6-80D96E6BAE83Q36630103-53478A6B-BC99-44EF-986B-0B6ECE8F8682Q36931357-9E3637E8-958D-4DCB-A53F-75E5682A98E0Q37142140-A2C3BB9C-97BD-4CA7-A505-9E3AD95A1267Q37379570-658B35B1-6780-4849-8F89-7CEA99091C49Q37661998-04D0A5F0-D9D1-463C-9225-45822BE6E5B2Q37810271-A4E5C42D-EA32-4B55-94BD-85CAA0CF1BF6Q37935867-A1043728-D80B-4371-A262-CB05860B3EBEQ38262596-723BC2E3-3385-4E66-89B5-85D35A5F081BQ39406969-90F47674-66FC-490E-9CDA-BFEFA08930C3Q40681392-208B9878-727A-401F-ADAE-FCAC9FBA2659Q46158135-E2A551ED-DE12-4069-AC98-308516B1B3DEQ47356017-0BC7CD49-1BE7-460F-81E7-4E55B0E6C0A8Q50770040-F2E6927F-239F-4BCA-861D-3799AB5603DAQ50770786-286B6828-1CD3-44F6-B42B-BC50EFEDDE13Q53270825-994C9AB3-5B39-4A98-9994-855440123009Q58481795-F623DA4C-5579-48F7-9257-6E657C2E68D7
P2860
Down's syndrome and acute lymphoblastic leukaemia: clinical features and response to treatment.
description
2001 nî lūn-bûn
@nan
2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Down's syndrome and acute lymp ...... res and response to treatment.
@ast
Down's syndrome and acute lymp ...... res and response to treatment.
@en
type
label
Down's syndrome and acute lymp ...... res and response to treatment.
@ast
Down's syndrome and acute lymp ...... res and response to treatment.
@en
prefLabel
Down's syndrome and acute lymp ...... res and response to treatment.
@ast
Down's syndrome and acute lymp ...... res and response to treatment.
@en
P2093
P2860
P356
P1476
Down's syndrome and acute lymp ...... res and response to treatment.
@en
P2093
Chessells JM
Harrison G
Richards SM
P2860
P304
P356
10.1136/ADC.85.4.321
P407
P577
2001-10-01T00:00:00Z